tbuckley/cabot-search huggingface dataset:
Evaluation of a Local Anesthetic Agent
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The promise of satellite clinics
Authors: J. M. Nelson
Journal: JAMA (1982)

A community hospital has developed a successful model for establishing affiliated primary care centers in semirural areas without the use of federal or foundation money. Unique features of the program include funding through community stock sales and ultimate control by a community board of directors. Additional features include the establishment of a for-profit, wholly owned subsidiary of the hospital; development of a complete range of planning, management, and recruitment services; retention of freedom of choice for referrals and hospitalizations by both patients and physicians; and a buy-out provision for the physicians. (<i>JAMA</i>1982;247:1854-1858)
Genotoxicity of 1,4-Benzoquinone and 1,4-Naphthoquinone in Relation to Effects on Glutathione and NAD(P)H Levels in V79 Cells
Authors: Gabriele Ludewig, Satish Dogra, Hansruedi Glatt
Journal: Environmental Health Perspectives (1989)

1,4-Benzoquinone is cytotoxic in V79 Chinese hamster cells and induces gene mutations and micronuclei. The cell-damaging effects of quinones are usually attributed to thiol depletion, oxidation of NAD(P)H, and redox-cycling involving the formation of semiquinone radicals and reactive oxygen species. To elucidate the role of these mechanisms in the genotoxicity of 1,4-benzoquinone, we measured various genotoxic effects, cytotoxicity, and the levels of glutathione, NADPH, NADH, and their oxidized forms all in the same experiment. 1,4-Naphthoquinone, which does not induce gene mutations in V79 cells, was investigated for comparative reasons. The quinones had a similar effect on the levels of cofactors. Total glutathione was depleted, but levels of oxidized glutathione were slightly increased. The levels of NADPH and NADH were reduced at high concentrations of the quinones with a simultaneous increase in the levels of NADP+ and NAD+. Both compounds induced micronuclei, but neither increased the frequency of sister chromatid exchange. Only 1,4-benzoquinone induced gene mutations. This effect was observed at low concentrations, where none of the other parameters studied was affected. When the cells were depleted of glutathione prior to treatment with the quinones, the induction of gene mutations and micronuclei remained virtually unchanged. We conclude that a) induction of micronuclei and glutathione depletion by the two quinones are not linked causally, b) 1,4-benzoquinone induces gene mutations by a mechanism different from oxidative stress and glutathione depletion, and c) glutathione does not fully protect the cells against the genotoxicity of quinones.
Lectures on the History of Medicine
Authors: A. Henry
Journal: BMJ (1860)

water-bath to a temperature of 194°, or until it boils.The precipitate is to be collected on a weighed filter, well washed, dried, and weighed.The albumen always contains a small quantity of earthy salts, which are obtained by incineration.The residue must be deducted from the weight of the dried precipitate.Albuminous Urine, from a patient with acute infla rmation of the kidney.The deposit contained numerous granular casts, but no fat-cells were present; specific gravity, 101 5; acid.The albumen coagulated by cheat and nitric acid.Analysis 40.Ini 100 parts of solids.Water .. .
Febrile Convulsions
Authors: James F. Hammill, Sidney Carter
Journal: New England Journal of Medicine (1966)

FEBRILE seizures remain a controversial topic so far as their cause, significance and treatment are concerned. Although the condition has been the subject of extensive studies conflicting data leave the questions unresolved. The magnitude of the problem is great, for it has been estimated1 that 5 per cent of children under the age of five years have convulsions, 40 per cent of these initial seizures being incited by fever.2 A general concept of the problem consists of a child between six months and five years of age who with intercurrent, nonCentral-nervous-system infection has a focal or generalized seizure in the . . .
CRAN-11. MULTIPLEXED IMMUNOFLUORESCENCE REVEALS POTENTIAL PD-1/PD-L1 PATHWAY VULNERABILITIES IN CRANIOPHARYNGIOMA
Authors: Shannon Coy, Rumana Rashid, Jia-Ren Lin, Ziming Du, Andrew M Donson, Todd C Hankinson, Nicholas K Foreman, Peter E Manley, Mark W Kieran, David A Reardon, Peter K Sorger, Sandro Santagata
Journal: Neuro-Oncology (2018)

Craniopharyngiomas are neoplasms of the sellar/parasellar region that are classified into adamantinomatous (ACP) and papillary (PCP) subtypes. Surgical resection of craniopharyngiomas is challenging, and recurrence is common, frequently leading to profound morbidity. BRAF V600E mutations render PCP susceptible to BRAF/MEK inhibitors, but effective targeted therapies are needed for ACP. We explored the feasibility of targeting the PD-1/PD-L1 immune checkpoint pathway in ACP and PCP. We quantified and mapped PD-L1 and PD-1 expression in ACP and PCP resections using immunohistochemistry, immunofluorescence, and RNA in situ hybridization. We used tissue-based cyclic immunofluorescence (t-CyCIF) to map the spatial distribution of immune cells and characterized cell cycle and signaling pathways in ACP tumor cells which intrinsically express PD-1. All ACP (15 ± 14% of cells, n=23) and PCP (35 ± 22% of cells, n=18) expressed PD-L1. In ACP, PD-L1 was predominantly expressed by tumor cells comprising the cyst-lining. In PCP, PD-L1 was highly-expressed by tumor cells surrounding the stromal fibrovascular cores. ACP also exhibited tumor cell-intrinsic PD-1 expression in whorled epithelial cells with nuclear beta-catenin. These cells exhibited evidence of increased downstream mTOR and MAPK signaling. Profiling of immune populations in ACP and PCP showed a modest density of CD8+ T-cells. ACP exhibit PD-L1 expression in the tumor cyst-lining and intrinsic PD-1 expression in cells proposed to comprise an oncogenic stem-like population. In PCP, proliferative tumor cells express PD-L1 in a continuous band at the stromal-epithelial interface. Targeting PD-L1 and/or PD-1 in both subtypes of craniopharyngioma might therefore be an effective therapeutic strategy.
LEGAL REQUIREMENTS FOR THE PRACTICE OF MEDICINE IN THE UNITED STATES.[Compiled for the Journal of the American Medical Association.]
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE DECREASING BIRTH RATE.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 4017: Clinical-genomic models of node-positive breast cancer: training, testing, and validation
Authors: Tzu-Ting Huang, Tzu-Pin Lu, Lei Lei, Skye H. Cheng
Journal: Cancer Research (2019)

Abstract Purpose: We developed and validated clinical-genomic models for stratifying node-positive breast cancer patients into low- and high-risk groups. Experimental design: The four datasets were (1) training group (n = 112); (2) testing group (n = 46); (3) validation group (n = 388); and (4) external validation group (n = 655). Patients who had undergone mastectomy or breast-conserving surgery and mRNA microarray analysis of their primary tumor tissue with a pathological stage of N0-N2 were enrolled. The validation groups included node-positive patients. Using pre-set cutoffs obtained from the training group, the models were tested and validated in the three other independent groups. Results: Two clinical-genomic models were developed to predict any recurrence (recurrence index [RI]-local recurrence [LR]) and distant recurrence (RI-DR). In the validation dataset, the RI-LR distinguished between low- and high-risk groups according to 10-year LR-free interval (LRFI; 100% vs. 93.3%, P = 0.014), relapse-free interval (RFI; 88.4% vs. 79.0%, P = 0.017), and relapse-free survival (RFS; 82.2% vs. 73.3%, P = 0.029). The RI-DR distinguished the low- from the high-risk group according to 10-year RFI (90.2% vs. 79.3%, P = 0.007) and RFS (81.0% vs. 74.2%, P = 0.031). RI-DR was associated with regional node irradiation in N1-N2 patients (hazard ratio: 3.7, 95% confidence interval 1.2-12.0) by multivariate analysis. The RI-DR- and RI-LR-gene panels performed similarly in the external validation dataset with hazard ratios of 1.27 (0.93-1.74, P= 0.127) and 1.54 (1.11-2.13, P= 0.0094), respectively, in high-risk patients. Discussion: The RI-DR shows better performance in partitioning N1-N2 patients into low- and high-risk groups than the RI-LR for any recurrence, although the latter is superior for predicting LRR. Citation Format: Tzu-Ting Huang, Tzu-Pin Lu, Lei Lei, Skye H. Cheng. Clinical-genomic models of node-positive breast cancer: training, testing, and validation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4017.
Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: A report from the Children’s Oncology Group study ANBL0531.
Authors: Clare Twist, Wendy B. London, Arlene Naranjo, Mary Lou Schmidt, E. Stanton Adkins, Peter Mattei, Sheena Cretella, Susan Lerner Cohn, Julie R. Park, John M. Maris
Journal: Journal of Clinical Oncology (2014)

10006 Background: This Phase III prospective reduction of therapy study used tumor biologic features to determine the minimal treatment needed to achieve excellent outcomes in patients with intermediate risk (IR) neuroblastoma (NB). Methods: Between 10/8/2007 and 6/30/2011, 464 patients enrolled; 401 had evaluable IR NB. Eligibility included newly diagnosed single copy MYCN NB and: age <12 years with stage 2A/B <50% resected or stage 3 with favorable biology, age <365 days with stage 3 or 4, and all patients <365 days with stage 4S, including those too ill to undergo biopsy. Toddlers age 365-<547 days with favorable biology stage 4 NB and age 365-<547 days with stage 3 and unfavorable histology (UH) received isotretinoin in addition to chemotherapy. Risk-stratification and therapy assignment utilized age, INSS stage, INPC, MYCN, and tumor ploidy. Therapy reduction was prescribed for tumors without loss of heterozygosity (LOH) at 1p36 and/or 11q23. Therapy included 2-8 courses of chemotherapy +/- surgery. Treatment endpoint for localized favorable biology tumors was partial response. Results: The 3-year EFS/OS for all IR patients was 83±3%/95±2%. The presence of 1pLOH and/or unbalanced 11qLOH was detected in 18% of IR tumors. To date, there were no deaths due to disease in patients with localized favorable biology tumors. Among 124 stage 4 patients <365 days, 3-year EFS/OS for favorable biology (n=60) was 90±5%/95±4%; for unfavorable biology (diploid and/or UH, irrespective of LOH, n=24) was 63±16%/76±13% and 65±14%/95±7% for tumors with LOH (n=20). Among 9 stage 4 toddlers there were 3 relapses; 3-year OS 100%. Eight of 46 patients with stage 4S NB died; 5 were due to complications of hepatomegaly. Conclusions: Further reduction of therapy and prospective refinement of treatment using genomic stratification achieved excellent survival in the majority of IR NB patients. Some unfavorable biology IR tumors may benefit from novel treatment strategies. Clinical trial information: NCT00499616.
Platelet antibody
Authors: Sinasi Özsoylu
Journal: American Journal of Hematology (1989)

Platelet AntibodyIn his review of platelet antibody detection methods, Dr. Schwartz [ 11 did not mention the Handin and Stossel method [2], which has been used successfully in the diagnosis of ITP by us.Using this method, antiplatelet antibodies were shown in the sera of all 103 patients with acute ITP and 100 cases following recovery from it.These antibodies were also shown in the sera of all 46 patients with chronic ITP and in 32 cases after recovery.The decrease of antiplatelet antibodies was significant in all these children following recovery (P < .001for acute ITP and P < .05for chronic ITP).
HSR20-112: Quantifying Caregiver Preferences for Attributes Associated With First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
Authors: Candice Yong, Brian Seal, M. Janelle Cambron-Mellott, Oliver Will, Martine C. Maculaitis, Kelly Clapp, Emily Mulvihill, Ion Cotarla, Ranee Mehra
Journal: Journal of the National Comprehensive Cancer Network (2020)

"HSR20-112: Quantifying Caregiver Preferences for Attributes Associated With First-Line Treatment of Metastatic Non-Small Cell Lung Cancer" published on 20 Mar 2020 by National Comprehensive Cancer Network.
REPORT OF A CASE OF WOOD ALCOHOL POISONING WITH UNUSUAL COMPLICATIONS
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Spirituality and the Dying Patient
Authors: Paul Rousseau
Journal: Journal of Clinical Oncology (2000)

Article Tools ART OF ONCOLOGY: WHEN THE TUMOR IS NOT THE TARGET Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2000.18.9.2000 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 10784643 Spirituality and the Dying Patient Paul RousseauxPaul RousseauSearch for articles by this author Show More From the Veterans Administration Medical Center and RTA HospicePhoenix; Arizona College of Osteopathic Medicine, Glendale; and Arizona State University, Tempe, AZ. https://doi.org/10.1200/JCO.2000.18.9.2000 First Page Full Text PDF Figures and Tables © 2000 by American Society of Clinical Oncology
Diploid hepatocytes drive physiological liver renewal in adult humans
Authors: Paula Heinke, Fabian Rost, Julian Rode, Thilo Welsch, Kanar Alkass, Joshua Feddema, Mehran Salehpour, Daniel Primetzhofer, Henrik Druid, Göran Possnert, Lutz Brusch, Olaf Bergmann
Journal: Journal of Hepatology (2020)
A 31-year-old woman with cough, hemoptysis, and bilateral hilar adenopathy
Authors: L. Nichols
Journal: JAMA (1983)

<h3>History</h3> A 31-year-old white woman was admitted to the hospital because of a nonproductive, progressively severe cough of six weeks' duration and hemoptysis of two weeks' duration. Treatment with penicillin V potassium, cephalexin monohydrate, and erythromycin sterate was ineffective. Radiological studies of the chest two weeks before admission showed early bilateral hilar adenopathy. Four days before admission, notable polyarthralgias and diffuse myalgias developed. Chest roentgenograms on admission, including plain film tomograms, showed a considerable increase in the hilar adenopathy but with no pulmonary infiltrates (Figure). The patient's history was unremarkable except for a single bout of transient pleuritis of unknown cause three years previously. Physical examination showed no abnormalities and specifically no peripheral lymphadenopathy. Results from multiple sputum smears and cultures were negative. The patient was anergic to PPD and control skin tests. Pulmonary function studies disclosed a first-second vital capacity (FEV<sub>1</sub>), a vital capacity, and diffusing capacity all
Clinical Comparison of Halothane (Fluothane) and Chloroform
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A new antibacterial agent, sodium cloxacillin monohydrate (Tegopen)
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Breast carcinoma metastatic to the uvea
Authors: R. A. Catalano
Journal: JAMA (1990)

A 45-year-old woman with a 1-year history of adenocarcinoma of the breast, metastatic to axillary lymph glands and both lungs, presented with a chief complaint of decreasing visual acuity. Examination revealed a best-corrected visual acuity of 20/50 in each eye. Isolated yellow subretinal masses, several disc diameters in size, with overlying pigment dispersion and serous retinal detachments were present in both eyes. Each macula was similarly affected (Fig 1). A 57-year-old woman with a similar history presented with an amelanotic-appearing fluffy white mass in the temporal iris and an anterior chamber angle of her left eye, with seeding into the anterior chamber (Fig 2). Both women had developed metastases to the vascular layer of the eye, the uvea. The uvea consists of the choroid posteriorly and the iris and ciliary body anteriorly. Metastases from adenocarcinoma can occur in either location, but more commonly involve the choroid.<sup>1</sup> Metastatic carcinoma to